Eli Lilly has officially launched its blockbuster diabetes and weight-loss drug, Mounjaro, in India, marking a significant step in addressing the country’s growing obesity and diabetes crisis. With this move, the U.S. pharmaceutical giant has outpaced its Danish rival, Novo Nordisk, in bringing a highly anticipated treatment to the world’s most populous nation.
India has seen a sharp rise in diabetes and obesity cases, making it a crucial market for weight-loss and glucose-control medications. Mounjaro, known for its effectiveness in lowering blood sugar levels and promoting weight loss, has gained global attention as a breakthrough therapy.
Novo Nordisk, which manufactures the widely popular weight-loss drug Wegovy, has yet to introduce its obesity treatment in India, giving Eli Lilly a first-mover advantage in the segment. The launch of Mounjaro is expected to reshape the country’s diabetes and obesity drug landscape as demand for innovative treatments rises.
